German laboratory CureVac announced on Wednesday that its leading COVID-19 vaccine candidate had only shown 47% efficacy, according to the interim analysis of a large-scale clinical trial, and was not fulfilling at this stage. the required criteria.
Read also: Covid: what is the ideal time between the two doses of vaccine?
The vaccine
"has reached a preliminary efficacy of 47% against COVID-19, regardless of its severity, not meeting the pre-specified statistical criteria of success
,
"
said in a statement the laboratory which signed a major contract of order with the European Union for this messenger RNA vaccine.